High Prevalence of Back Pain and Axial Spondyloarthropathy in Patients with Hidradenitis Suppurativa

Sylke Schneider-Burrusa, Ellen Witte-Haendelb,c, Demetrios Christoub,c, Benedetta Rigonid, Robert Sabatb,c, Gerd Diederichsd

a Department of Dermatology and Allergy, b Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, c Psoriasis Research and Treatment Center, and d Department of Radiology, Charité University Hospital, Berlin, Germany

Furthermore, there was no correlation between these parameters and the degree of SpA. Limitations: Only patients with moderate/severe HS (Hurley stage II and III) in genitofemoral/perianal sites were analysed via MRI scans. Conclusion: Back pain and SpA are very common among patients with moderate/severe HS. Neither medical history nor clinical parameters provide hints for the presence of SpA.

Introduction

Hidradenitis suppurativa (HS, also referred to as acne inversa) is a chronic inflammatory disease of terminal hair follicles, which affects the intertriginous skin of axillary, genitofemoral and perianal sites. It is estimated that approximately 1% of the general population suffer from HS [3, 4] with a higher prevalence of up to 4% in young females [3].

The aetiology of HS is unknown so far. Smoking, obesity, hormonal factors, and a putative genetic background...

© 2016 S. Karger AG, Basel
may play a role in disease development and/or course. Initially, hyperplasia of the follicular epithelium leads to stasis in the hair follicle unit, formation of subcutaneous nodules, and propagation of bacteria [5–7]. Later, the nodules spontaneously rupture or melt, forming painful deep dermal abscesses. The content of ruptured nodules strengthens inflammation that further supports purulent exudate formation. In the late stage, lesions are characterized by painful, fistulating sinuses and large indurated inflammatory plaques with extensive scarring [5]. At the molecular level, the HS lesions are characterized by strong inflammation with various aspects of immune dysregulation [8].

In addition to the cutaneous symptoms, a high proportion of HS patients suffer from severe metabolic alterations [9, 10]. These alterations include obesity, elevated fasting blood glucose levels and dyslipidaemia, and may be caused or potentiated by chronic inflammation observed in HS patients.

Several chronic inflammatory diseases affecting epithelial tissues like psoriasis, Crohn’s disease, or colitis ulcerosa are frequently associated with spondyloarthropathy (SpA) [11], which may significantly reduce the quality of life of these patients.

Cigarette smoking has been suggested to be associated with the progression of SpA and might even have a dose-dependent impact on the course of structural damage in axial SpA [12, 13]. Moreover, an association between obesity and SpA has been communicated, with obesity being associated with a poor clinical outcome [14].

Since an association of HS and SpA is largely unknown so far, the aim of this study was to assess the prevalence of back pain in a large cohort of HS patients by means of questionnaires and to analyse radiological signs for SpA in magnetic resonance imaging (MRI) scans of the pelvis.

**Methods**

For further details, see the supplementary materials (for all online suppl. material, see www.karger.com/doi/10.1159/000448838) [15–20] (fig. 1; table 1).

**Results**

**Prospective Questionnaire Analysing the Prevalence of Back Pain**

Analysing the survey in 100 patients with HS, we learned that 71% of HS patients were afflicted by back pain (fig. 2). 33.8% of affected patients reported very frequent or permanent pain, 66.2% of the affected patients

---

**Table 1.** Characteristics of patients of the questionnaire survey study group and the MRI study group

<table>
<thead>
<tr>
<th></th>
<th>Questionnaire survey</th>
<th>MRI study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>38.77 ± 1.00</td>
<td>41.07 ± 1.74</td>
</tr>
<tr>
<td>Females, %</td>
<td>66</td>
<td>43.48</td>
</tr>
<tr>
<td>Males, %</td>
<td>34</td>
<td>56.52</td>
</tr>
<tr>
<td>Age at onset, years</td>
<td>25.61 ± 1.05</td>
<td>29.11 ± 1.92</td>
</tr>
<tr>
<td>Duration of disease, years</td>
<td>13.26 ± 0.94</td>
<td>12.98 ± 1.65</td>
</tr>
<tr>
<td>BMI</td>
<td>29.44 ± 0.68</td>
<td>28.22 ± 0.65</td>
</tr>
</tbody>
</table>
suffered from occasional pain. In 76.1% of HS patients the back pain was located in the lumbar region (fig. 2).

There were no differences in age at onset of HS, disease duration, smoking incidence, and frequency of a positive HS family history between HS patients without and with back pain or patients with occasional, very frequent or permanent pain (data not shown). The assessment of clinical parameters revealed no differences in body height, body weight, body mass index (BMI), and disease severity between HS patients with or without back pain either.

The only significant difference between clinical parameters of patients without back pain, patients with occasional pain, and patients with very frequent or permanent pain was found concerning the patients’ height. In fact, patients suffering from very frequent or permanent pain were shorter than patients with occasional or no pain (169.5, 176.2, and 174.3 cm, respectively, p = 0.003). However, there was no significant difference regarding weight between HS patients without pain and with very frequent or permanent pain (83.2, 93.9, and 86.5 kg, respectively), ruling out body mass influences on the identified association of HS with back pain.

Retrospective MRI Study Analysing the Prevalence of SpA

In order to identify the reason for the back pain in HS, MRI scans of the pelvis that had been undertaken in HS patients as preparation for the surgical excision of HS were re-evaluated for abnormalities in the sacroiliac joints. In 56.5% of these patients typical changes indicative of SpA were found (fig. 3a). A total of 39.1% of investigated HS patients showed characteristics of acute inflammation (fig. 3a, 4a), consisting in various degrees of joint effusion, synovitis, erosions and subchondral oedema. In most cases, these were mild to moderate alterations (table 2, fig. 3b). Furthermore, MRI scans of 32.6% of HS patients showed signs of chronic SpA activity at the sacroiliac joints (fig. 3a, 4b). These signs were again various degrees of the manifestation of subchondral sclerosis and widening or narrowing of the joint space as far as definitive ankylosis bilaterally. In most cases, the chronic alterations were of first grade (table 2, fig. 3b). Interestingly, 15.2% of HS patients simultaneously presented signs of acute and chronic SpA (fig. 3a).

Relevant signs for osteoarthritis, posttraumatic joint alterations, osteitis condensans ilii, or pyogenic sacroiliitis were not found in any patient of this study.

The evaluation of available anamnestic parameters of the MRI cohort showed no significant differences between HS patients with and without SpA regarding the following parameters: age at time of MRI, age at onset of HS, disease duration, smoking habits, and ethnicity (table 3). The assessment of clinical data also demonstrated similar levels for body height, body weight, BMI, and disease severity between HS patients with and without SpA. For a limited number of patients, further clinical data were available, such as white blood cell count (n = 33) and C-reactive protein (n = 25). Both of these inflammatory markers were higher in the SpA group, but these differences were not significant, possibly due to the small number of samples.

Furthermore, there was no correlation between any of the parameters above and the degree of SpA (data not shown).
Discussion

In this current study we analysed the prevalence of back pain in patients suffering from HS and demonstrated that back pain is common in HS patients. In fact, 71% of HS patients suffer from back pain. Sacroiliitis as the possible cause of lower back pain may be difficult to detect, as it is commonly mistaken for other entities such as disc herniations or osteoarthritis. Interestingly, 56.5% of non-preselected HS patients in our investigation harboured clear radiological signs of SpA pointing to a substantial proportion in view of the overall prevalence of SpA being 1% [21].

An association between HS and SpA was a matter of suggestion by few publications in the past. Rosner et al. [22] were the first to report cases of SpA in HS patients. This initial description from 1982 was followed by a number of case reports and few small case series [21, 23–26]. The observed radiographic alterations in HS patients were described as indistinguishable from those of other seronegative forms of SpA [27]. Our precise MRI analyses [28, 29] disclosed a surprisingly high number of typical changes suggesting SpA-related sacroiliitis in 56.5% of the patients.

Table 3. Characteristics of patients with and without radiological signs of SpA

<table>
<thead>
<tr>
<th></th>
<th>Patients without signs of SpA</th>
<th>Patients with signs of SpA</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>20</td>
<td>26</td>
<td>0.676</td>
</tr>
<tr>
<td>Sex ratio female/male</td>
<td>8/12</td>
<td>12/14</td>
<td></td>
</tr>
<tr>
<td>Age at MRI, years</td>
<td>40.8 ± 10.8</td>
<td>41.3 ± 12.8</td>
<td>0.610</td>
</tr>
<tr>
<td>Hurley classification</td>
<td></td>
<td></td>
<td>0.334</td>
</tr>
<tr>
<td>I</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>15 (75%)</td>
<td>16 (62.5%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>5 (25%)</td>
<td>10 (38.5%)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>German</td>
<td>20</td>
<td>23</td>
<td>0.116</td>
</tr>
<tr>
<td>Turkish</td>
<td>0</td>
<td>2</td>
<td>0.205</td>
</tr>
<tr>
<td>African-European</td>
<td>0</td>
<td>1</td>
<td>0.373</td>
</tr>
<tr>
<td>Current smokers (n = 28), %</td>
<td>81.8</td>
<td>92.9</td>
<td>0.457</td>
</tr>
</tbody>
</table>

The p values calculated by the \( \chi^2 \) test (sex distribution, Hurley classification, ethnicity, smoking habit) or Mann-Whitney U test (age) are indicated.
Most of the case series and case reports in the past suggested the association of HS and SpA to mainly concern male African-American or Afro-Caribbean patients [22, 25, 26, 30]. In our study we included 1 male patient of African ancestry, 2 male Turkish patients and 43 patients of German origin. 23 of the latter had radiological signs of SpA, indicating that the high risk for developing SpA among HS patients is independent of their ancestry.

Recently the first prospective study investigating the presence of SpA in patients with HS has found an elevated overall rate of 3.7% [31]. Within the screened 640 patients with HS, 184 (29%) had musculoskeletal symptoms, considerably fewer than in the present study. 15 patients underwent MRI of the sacroiliac joints and the spine, of whom 20% showed active inflammatory lesions in the spine, 20% in the sacroiliac joints and 20% structural lesions of the sacroiliac joints. 31 additional patients were investigated with conventional radiographs, showing radiological signs of sacroiliitis (10 patients) and syndesmophytes (4 patients). Since only patients with clinical signs of inflammatory rheumatological diseases were screened by radiography/MRI, the rate of alterations in the sacroiliac joint in the remaining 594 (asymptomatic) patients remains unknown.

Our finding that SpA is dramatically common in patients with severe and moderate HS leaves us with two open questions: How does SpA develop in patients with HS? What treatment should be recommended?

Apart from the fact that SpA is generally an inflammatory disorder, the pathogenesis of SpA in HS patients is
unclear. In contrast to other types of seronegative forms of SpA, an association with the histocompatibility antigen HLA-B27 in HS patients does not seem to exist [22, 27, 32]. Importantly, we did not observe any association between body height, body weight, BMI, smoking habits and the appearance of back pain or SpA, suggesting no major influence of lifestyle on the occurrence of back pain and SpA. Furthermore, the age at HS onset, duration of HS, and severity of skin alterations was similar in patient groups with and without back pain or SpA indicating that the skin alterations did not have an excessive influence on SpA or back pain. However, an aggravation of joint symptoms concurring with flares of skin disease has been reported by two studies [24, 26]. All these facts might suggest that a genetic predisposition for SpA may exist in HS patients and that inflammatory skin alterations could induce SpA in these predisposed patients. The latter is supported by the observation that a surgical treatment of HS may improve SpA [22].

Successful systemic treatment in cases of symptomatic SpA in HS has been reported for non-steroidal anti-inflammatory drugs [24], systemic steroids [24], isotretinoin [23], sulphasalazine [25], cyclophosphamide [30] and anti-tumour necrosis factor (TNF) therapy [24, 33]. In fact, Lim et al. [24] described an HS patient with SpA who was asymptomatic and free of any skin lesions after treatment with adalimumab. Recently, anti-TNF drugs have proven effective in the therapy of severe cases of HS [34, 35]. Moreover, a high degree of spinal inflammation visible on MRI is predictive of a successful response to anti-TNF therapy [36, 37]. These findings suggest a positive effect of anti-TNF therapy in patients with severe HS also suffering from SpA but controlled studies need to be conducted to ascertain this assumption.

Conclusions

Patients suffering from HS of the groin, buttocks or perianal area are at high risk of developing SpA. This finding adds another aspect to the number of disorders lately found to be associated with HS and helps to understand HS as a systemic inflammatory disease. Patients with HS should be monitored for inflammatory joint pain and when clinical symptoms occur, the possibility of SpA should be ruled out ideally by MRI scanning. Active SpA in HS should be treated – preferably as part of a prospective investigation.

Acknowledgements

The authors acknowledge Annette Buss, Brigitte Ketel, and Beate Pust for their steady excellent technical assistance.

Statement of Ethics

Both substudies presented in this paper were approved by the ethical review board of the Charité University Hospital, Berlin, Germany.

Disclosure Statement

The authors declare no conflicts of interest.

References

12 Poddubnyy D, Haibel H, Listing J, Marker-Sartorius K, Emtestam L, Jemec GB, Lapins J:
10 Tzellos T, Zouboulis CC, Gulliver W, Cohen Dougados M, Demattei C, van den Berg R,
9 Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A,
1432.

Dermatology 2016;232:606–612

DOI: 10.1159/000448838

Schneider-Burrus/Witte-Haendel/
Christou/Rigoni/Sabat/Diederichs


